drugset / Trial / NCT00068302

Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma

NCT00068302

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy such as sirolimus use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus in treating young patients with relapsed or refractory acute leukemia or non-Hodgkin's lymphoma.

Timeline

Start
2003-01
Primary completion
2009-04
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule Oral

Indications